WO2013038016A3 - Monoclonal antibodies for detection of high-risk human papillomavirus oncoprotein e7 - Google Patents

Monoclonal antibodies for detection of high-risk human papillomavirus oncoprotein e7 Download PDF

Info

Publication number
WO2013038016A3
WO2013038016A3 PCT/EP2012/068271 EP2012068271W WO2013038016A3 WO 2013038016 A3 WO2013038016 A3 WO 2013038016A3 EP 2012068271 W EP2012068271 W EP 2012068271W WO 2013038016 A3 WO2013038016 A3 WO 2013038016A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
detection
human papillomavirus
risk human
oncoprotein
Prior art date
Application number
PCT/EP2012/068271
Other languages
French (fr)
Other versions
WO2013038016A2 (en
Inventor
Olle Nilsson
Christian FERMÉR
Maria LIDQVIST
Original Assignee
Fujirebio Diagnostics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Diagnostics Ab filed Critical Fujirebio Diagnostics Ab
Publication of WO2013038016A2 publication Critical patent/WO2013038016A2/en
Publication of WO2013038016A3 publication Critical patent/WO2013038016A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Disclosed herein are monoclonal antibodies for an improved detection of HPV-associated pre-malignant lesions, malignant lesions and invasive cancer. Furthermore, methods and uses of the monoclonal antibodies for the detection, diagnosis and/or prognosis HPV-associated pre-malignant lesions, malignant lesions and invasive cancer are disclosed.
PCT/EP2012/068271 2011-09-16 2012-09-17 Monoclonal antibodies for detection of high-risk human papillomavirus oncoprotein e7 WO2013038016A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535815P 2011-09-16 2011-09-16
US61/535,815 2011-09-16

Publications (2)

Publication Number Publication Date
WO2013038016A2 WO2013038016A2 (en) 2013-03-21
WO2013038016A3 true WO2013038016A3 (en) 2013-05-10

Family

ID=46851522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/068271 WO2013038016A2 (en) 2011-09-16 2012-09-17 Monoclonal antibodies for detection of high-risk human papillomavirus oncoprotein e7

Country Status (1)

Country Link
WO (1) WO2013038016A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105504049B (en) 2014-09-26 2019-07-05 艾托金生物医药（苏州）有限公司 The relevant HPV E7 protein monoclonal antibody of cervical carcinoma and its application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026731A1 (en) * 2003-09-17 2005-03-24 Amynon Biotech Gmbh Combination of anti-hpv-16 and 18 antibodies and uses thereof
WO2006085822A1 (en) * 2005-02-10 2006-08-17 Canag Diagnostics Ab Site-specific immunization in order to establish antibodies with specificity for the e7 oncoprotein of high-risk hpvs
WO2011101122A1 (en) * 2010-02-16 2011-08-25 Österreichische Akademie der Wissenschaften Anti-hpv e7 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026731A1 (en) * 2003-09-17 2005-03-24 Amynon Biotech Gmbh Combination of anti-hpv-16 and 18 antibodies and uses thereof
WO2006085822A1 (en) * 2005-02-10 2006-08-17 Canag Diagnostics Ab Site-specific immunization in order to establish antibodies with specificity for the e7 oncoprotein of high-risk hpvs
WO2011101122A1 (en) * 2010-02-16 2011-08-25 Österreichische Akademie der Wissenschaften Anti-hpv e7 antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KRCHNAK V ET AL: "IDENTIFICATION OF SEROREACTIVE EPITOPES OF HUMAN PAPILLOMAVIRUS TYPE 18 E7 PROTEIN BY SYNTHETIC PEPTIDES", ACTA VIROLOGICA, ACADEMIA PRAGUE, PRAGUE, CS, vol. 37, no. 5, 1 October 1993 (1993-10-01), pages 395 - 402, XP009050452, ISSN: 0001-723X *
KRCHNAK V ET AL: "SYNTHETIC PEPTIDES DERIVED FROM E7 REGION OF HUMAN PAPILLOMAVIRUS TYPE 16 USED AS ANTIGENS IN ELISA", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 71, no. 11, 1 January 1990 (1990-01-01), pages 2719 - 2724, XP002635493, ISSN: 0022-1317, DOI: 10.1099/0022-1317-71-11-2719 *
M. LIDQVIST ET AL: "Detection of human papillomavirus oncoprotein E7 in liquid-based cytology", JOURNAL OF GENERAL VIROLOGY, vol. 93, no. 2, 1 February 2012 (2012-02-01), pages 356 - 363, XP055045456, ISSN: 0022-1317, DOI: 10.1099/vir.0.034884-0 *

Also Published As

Publication number Publication date
WO2013038016A2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2013089882A3 (en) Recurrent gene fusions in breast cancer
CA2840149C (en) Methods and nucleic acids for determining the prognosis of a cancer subject
WO2015031694A3 (en) Oligonucleotide probes and uses thereof
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
WO2011034906A3 (en) Recurrent gene fusions in prostate cancer
EP2427763A4 (en) Identification of high grade or cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
HRP20160764T1 (en) Papillomavirus pseudoviruses for detection and therapy of tumors
WO2012068383A3 (en) ncRNA AND USES THEREOF
MX2013000917A (en) Methods of detecting diseases or conditions using phagocytic cells.
EP4303584A3 (en) Methods for detecting signatures of disease or conditions in bodily fluids
WO2011008696A3 (en) Diagnostic methods and compositions for treatment of cancer
WO2012040459A3 (en) Beta-catenin targeting peptides and uses thereof
WO2011149909A3 (en) Class i mhc phosphopeptides for cancer immunotherapy and diagnosis
WO2011088385A3 (en) Compositions and methods for detecting cancer
WO2012103250A3 (en) Colon cancer gene expression signatures and methods of use
EP2575604A4 (en) Apparatus, systems, methods and computer-accessible medium for analyzing information regarding cardiovascular disease(s) and function(s)
WO2012015904A3 (en) Biomarkers for prostate cancer and methods using the same
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
HK1209460A1 (en) Prdm14 and fam19a4, molecular diagnostic markers for hpv-induced invasive cancers and their high-grade precursor lesions hpv prdm14 fam19a4
WO2015148979A8 (en) Compositions and methods related to diagnosis of prostate cancer
WO2011043809A9 (en) Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
WO2011097509A3 (en) Hypoxia-related gene signatures for cancer classification
GB0815846D0 (en) diagnosis, prognosis and imaging of disease
WO2011093675A3 (en) Biological method and system for selecting diagnostic marker for subtype of lung cancer directly from blood, and marker for diagnosis of lung cancer selected with the system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12759156

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12759156

Country of ref document: EP

Kind code of ref document: A2